At SXSW, Cuban and eMed CEO Draw Contrast Between Them and Other “Marketing” Companies

Why It Matters

The alliance could expand low‑cost GLP‑1 access for millions of employees while showcasing a care‑focused model that may out‑perform high‑churn marketing‑only platforms.

Key Takeaways

• eMed partners with Cost Plus Drugs for GLP‑1 access.
• eMed reports 90% year‑long GLP‑1 retention.
• Competitors like Ro, Hims & Hers have 50‑60% churn.
• Weekly check‑ins and facial recognition drive adherence.
• Pricing pressure rises after TrumpRx and Novo deal.

Pulse Analysis

The GLP‑1 market has become a battleground as demand outstrips supply, prompting a wave of direct‑to‑consumer firms that rely heavily on marketing spend rather than clinical oversight. Companies such as Ro and Hims & Hers have attracted users with low‑cost ads but suffer churn rates of 50‑60 %, reflecting limited engagement and safety concerns around compounded products that sit outside FDA regulation.

eMed’s approach diverges sharply by embedding continuous monitoring into its digital health platform. Users complete weekly 60‑second check‑ins that capture facial recognition, weight data, and dosage adjustments, fostering accountability and a reported 90 % retention after one year. The new partnership with Cost Plus Drugs adds a pricing lever, allowing employer‑sponsored programs to source FDA‑approved GLP‑1s at substantially reduced costs, a critical factor given the drugs’ high price tags.

Industry‑wide, the collaboration signals a shift toward value‑based, employer‑driven obesity solutions. Policy initiatives like the TrumpRx coupon program and Novo Nordisk’s renewed distribution agreement with Hims & Hers underscore the pressure to lower prices while maintaining safety. As more employers adopt eMed’s model, the balance may tip away from pure marketing entities toward integrated care ecosystems that combine affordability, adherence, and clinical oversight, reshaping how the U.S. tackles the costly obesity epidemic.